AC Immune SA announced positive preliminary Phase 1 data for ACI-19764, an orally administered small molecule inhibitor of the NLRP3 inflammasome. The drug demonstrated safety and tolerability in healthy volunteers across single and multiple ascending dose cohorts up to 20mg per day, with no serious adverse events. Key findings included confirmed cerebrospinal fluid penetration, a serum half-life exceeding 30 hours, and dose-dependent inhibition of IL-1beta release at daily doses of 10mg or less. The company has initiated dosing in a cardiovascular risk cohort to evaluate anti-inflammatory activity via hsCRP reduction, with initial results expected by year-end. Full Phase 1/1b trial results are anticipated in the first half of 2027. AC Immune SA is a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases.
